Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for autoimmune and inflammatory diseases. Its lead program, claseprubart, and pipeline candidate DNTH212 are being advanced through preclinical and clinical development, with the company relying on collaborations and third-party manufacturers rather than owning commercial infrastructure.

−8 733,9 %

−7 973,3 %

−67,3 %

13.32

13.32

— Dianthus Therapeutics, Inc. /DE/
%
Lead antibody program55% Claseprubart is the company's lead biologic candidate being developed for autoimmune and inflammatory indications.
Pipeline candidate20% DNTH212 is a follow-on product candidate intended to broaden the company's therapeutic pipeline.
Collaboration and license revenue25% Milestone, upfront, and reimbursable-cost revenue from licensing and development collaborations.

Dianthus does not sell approved commercial products today; its current counterparties are collaboration partners,...

  • Development and licensing partnersprimary

    Tenacia, Leads, and similar partners buy rights, development access, or collaboration exposure to Dianthus assets.

  • Clinical trial ecosystemprimary

    CROs, CDMOs, investigators, and sites provide trial execution, manufacturing, and data generation.

  • Future treating physicians and payorsemerging

    Neurologists, hospitals, and insurers would adopt and reimburse approved therapies if clinical value is compelling.

The company is headquartered in the United States and its business is primarily organized around U.S...

  • •Headquartered in the United States
  • •No disclosed country-level revenue concentration in the excerpts
  • •R&D and corporate activity are centered in the U.S.
  • •Third-party trial and manufacturing work may be global
  • •Future commercial geography will depend on approval and launch markets

Dianthus is focused on advancing claseprubart and DNTH212 through development while preserving capital through a lean,...

01
Advance clinical development of lead and pipeline assetsshort-term

Clinical success is the main value driver for a company with no approved products.

02
Maintain collaboration revenue and strategic partnershipsshort-term

Partner payments and milestones help fund operations and validate the platform.

03
Preserve capital and extend runwaymedium-term

The company is loss-making and will likely need additional capital before commercialization.

The company is highly exposed to clinical, regulatory, and financing risk because it has no approved products and...

critical

Clinical development failure

The company has not completed late-stage trials, so asset value is still unproven.

Scope
Claseprubart and DNTH212
Materiality
high
high

Financing risk

Operations are loss-making and the company expects to raise additional capital if needed.

Scope
Cash runway and dilution risk
Materiality
high
high

Competition in autoimmune indications

Approved therapies and competing pipelines may offer better safety, efficacy, or dosing.

Scope
gMG, MMN, CIDP and related markets
Materiality
high
high

Third-party execution risk

Trials and manufacturing are outsourced, reducing direct control over timing and quality.

Scope
CROs, CDMOs, investigators, and collaborators
Materiality
medium
medium

Patient enrollment risk

Competing trials and approved products can slow recruitment and extend timelines.

Scope
Autoimmune and inflammatory clinical studies
Materiality
medium
Collaboration and license revenue recognition
Can cause uneven quarterly revenue and make trend analysis difficult
Research and development expense timing
Directly drives operating loss and period-to-period volatility
Fair value of investments
Can move earnings and liquidity presentation
Foreign currency exchange
Usually modest, but can add noise to quarterly results

Indaptus Therapeutics, Inc.

INDP · Pharmaceutical Preparations

Ventyx Biosciences, Inc.

Pharmaceutical Preparations

Liminatus Pharma, Inc.

LIMN · Biological Products, (No Diagnostic Substances)

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

Anebulo Pharmaceuticals, Inc.

ANEB · Pharmaceutical Preparations

: 28/04/2026